Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimizing damage to healthy tissues.
Short position
Telix Pharmaceuticals (ASX:TLX) has 10.62% of its shares on issue reported as short positions as of 5 Oct 2026, or about 36,146,864 shares. Over the past 30 days that figure has risen 0.21 percentage points, and over 90 days it has fallen 1.24 percentage points. Its highest recorded short interest was 16.51% in April 2026. TLX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Telix Pharmaceuticals (TLX) company profile
Profile, insiders and operations
Company
AI-generated research profile of Telix Pharmaceuticals
TLX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links